Why the study?
Recent studies have evaluated dabigatran to determine its safety and efficacy across diverse cardiovascular indications, warranting a comprehensive review of its role.
This comprehensive review summarizes the role, safety, and efficacy of dabigatran across a wide spectrum of cardiovascular and thromboembolic conditions.
Supports dabigatran use in thromboembolic conditions; extends evidence synthesis but leaves open need for updated RCTs.
Dabigatran, a direct thrombin inhibitor, has robust data for the treatment of deep venous thrombosis and pulmonary embolism, stroke prevention in non-valvular atrial fibrillation, and the prophylaxis of venous thromboembolism (VTE) after knee and hip replacement. Recent studies have evaluated dabigatran to determine its safety and efficacy in such conditions as VTE in malignancy, coronary artery disease, mechanical and bioprosthetic valves, and antiphospholipid syndrome. This article provides a comprehensive review on the role of dabigatran in various cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Javed et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: